Claims
- 1. A combination for ameliorating the effects of exposure to a bacterial bioterror weapon, such as Bacillus Anthracis, comprising:
in a pharmaceutically acceptable carrier, at least one therapeutic dose of NAC and a therapeutic dose of at least one antibiotic to said bacterial bioterror weapon.
- 2. The combination according to claim 1, further comprising:
a therapeutic dose of Selenium.
- 3. The claim according to claim 2, further comprising:
a therapeutic dose of DHEA.
- 4. A combination for prophylaxis of an impending bacterial bioterror weapon comprising:
in a pharmaceutically acceptable carrier, a therapeutic dose of NAC and a prophylactic dose of at least one general antibiotic to said impending bacterial bioterror weapon.
- 5. The combination according to claim 4, further comprising:
a therapeutic dose of Selenium.
- 6. The claim according to claim 5, further comprising:
a therapeutic dose of DHEA.
- 7. The combination according to claim 4, further comprising:
said at least one general antibiotic being selected from the group of Penicillins such as Penicillin, Ampicillin, Nafcillin, or Piperacillin, Beta-lactamase inhibitors such as Aztreonam, Imipenem, Ampicillin/sulbactam (Augmentum) or Pipercillin/tazobactam, or a subgroup including Beta-lactams such as Ceftriaxone, Cefuroxime, Quinolones such as Ciprofloxacin, Ofloxacin, Gatifloxacin or Trovafloxacin, Tetracyclines such as Tetracycline, Doxycycline, or Minocycline, and Macrolides such as Erythromycin, Clarithromycin, or Azithromycin.
- 8. The claim according to claim 7, further comprising:
a therapeutic dose of Selenium.
- 9. The claim according to claim 8, further comprising:
a therapeutic dose of DHEA.
- 10. A combination for ameliorating the effects of exposure to a viral bioterror weapon, such as smallpox, comprising:
in a pharmaceutically acceptable carrier, a therapeutic dose of NAC and a therapeutic dose of at least one antiviral agent to said viral bioterror weapon.
- 11. The combination according to claim 10, further comprising:
a therapeutic dose of Selenium.
- 12. The claim according to claim 11, further comprising:
a therapeutic dose of DHEA.
- 13. A combination for prophylaxis of an impending viral bioterror weapon comprising:
in a pharmaceutically acceptable carrier, a therapeutic dose of NAC and a prophylactic dose of at least one general antiviral agent to said impending viral bioterror weapon.
- 14. The combination according to claim 13, further comprising:
a therapeutic dose of Selenium.
- 15. The claim according to claim 14, further comprising:
a therapeutic dose of DHEA.
- 16. The combination according to claim 13, further comprising:
said at least one general antiviral agent being selected from the group of cidofovir, Broad spectrum antivirals such as the Triazole carboxamine, Ribavirin, protease inhibitors such as Saquinavir, Ritonavir, Indinavir, and Nelfinavir, tricyclic amines such as Amantadine and Rimantadine, Meuraminic acid mimetics such as Relenza and Tamiflu, small cyclics such as Pleconaril, Nucleoside analogues such as Vidarabine, Acyclovir, Gancyclovir, valganciclovir, Nucleoside Reverse transcriptase inhibitors such as Zidovudine (AZT), Didanosine (dd1), Zaocaitabine (ddC), Stravudine (d4T), and Lamivudine (3TC), and Non-Nucleoside Reverse transcriptase inhibitors such as Nevirapine and Delaviridine,
- 17. The claim according to claim 16, further comprising:
a therapeutic dose of Selenium.
- 18. The claim according to claim 17, further comprising:
a therapeutic dose of DHEA.
- 19. A combination for ameliorating the side effects of a vaccine against a bioterror weapon or disease more generally, comprising:
in a pharmaceutically acceptable carrier, said vaccine, and a therapeutic dose of NAC.
- 20. The combination according to claim 19, further comprising:
said therapeutic dose of NAC being selected from the group of water soluble NAC compounds.
- 21. The claim according to claim 20, further comprising:
a therapeutic dose of Selenium.
- 22. The claim according to claim 21, further comprising:
a therapeutic dose of DHEA.
- 23. A combination for prophylaxis of an impending potential combined viral and bacterial bioterror weapon comprising:
in a pharmaceutically acceptable carrier, a therapeutic dose of NAC, a prophylactic dose of at least one general antiviral agent, and a prophylactic dose of at least one general antibiotic.
- 24. The combination according to claim 23, further comprising:
a therapeutic dose of Selenium.
- 25. The claim according to claim 24, further comprising:
a therapeutic dose of DHEA.
- 26. The combination according to claim 23, further comprising:
said at least one general antiviral agent being selected from the group of cidofovir, Broad spectrum antivirals such as the Triazole carboxamine, Ribavirin, protease inhibitors such as Saquinavir, Ritonavir, Indinavir, and Nelfinavir, tricyclic amines such as Amantadine and Rimantadine, Meuraminic acid mimetics such as Relenza and Tamiflu, small cyclics such as Pleconaril, Nucleoside analogues such as Vidarabine, Acyclovir, Gancyclovir, valganciclovir, Nucleoside Reverse transcriptase inhibitors such as Zidovudine (AZT), Didanosine (dd1), Zaocaitabine (ddC), Stravudine (d4T), and Lamivudine (3TC), and Non- Nucleoside Reverse transcriptase inhibitors such as Nevirapine and Delaviridine; and said at least one general antibiotic being selected from the group of_Penicillins such as Penicillin, Ampicillin, Nafcillin, or Piperacillin, Beta-lactamase inhibitors such as Aztreonam, Imipenem, Ampicillin/sulbactam (Augmentum) or Pipercillin/tazobactam, or a subgroup including Beta-lactams such as Ceftriaxone, Cefuroxime, Quinolones such as Ciprofloxacin, Ofloxacin, Gatifloxacin or Trovafloxacin, Tetracyclines such as Tetracycline, Doxycycline, or Minocycline, and Macrolides such as Erythromycin, Clarithromycin, or Azithromycin.
- 27. The claim according to claim 26, further comprising:
a therapeutic dose of Selenium.
- 28. The claim according to claim 27, further comprising:
a therapeutic dose of DHEA.
- 29. A method of ameliorating the effects of exposure to a bacterial bioterror weapon such as Bacillus Anthracis comprising the following steps:
administering in a pharmaceutically acceptable carrier at least one therapeutic dose of NAC; and administering at least one therapeutic dose of at least one antibiotic to said bacterial bioterror weapon.
- 30. The method according to claim 29, further comprising the additional step:
administering a therapeutic dose of selenium.
- 31. The method according to claim 30, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 32. A method of prophylaxis of impending exposure to a bacterial bioterror weapon such as Bacillus Anthracis comprising the following steps:
administering in a pharmaceutically acceptable carrier a course of therapeutic doses of NAC; and administering a course of prophylactic doses of at least one antibiotic to said bacterial bioterror weapon.
- 33. The method according to claim 32, further comprising the additional step:
administering a therapeutic dose of selenium.
- 34. The method according to claim 33, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 35. The method according to claim 32, further comprising:
selecting said at least one general antibiotic from the group of Penicillins such as Penicillin, Ampicillin, Nafcillin, or Piperacillin, Beta-lactamase inhibitors such as Aztreonam, Imipenem, Ampicillin/sulbactam (Augmentum) or Pipercillin/tazobactam, or a subgroup including Beta-lactams such as Ceftriaxone, Cefuroxime, Quinolones such as Ciprofloxacin, Ofloxacin, Gatifloxacin or Trovafloxacin, Tetracyclines such as Tetracycline, Doxycycline, or Minocycline, and Macrolides such as Erythromycin, Clarithromycin, or Azithromycin.
- 36. The method according to claim 34, further comprising the additional step:
administering a therapeutic dose of selenium.
- 37. The method according to claim 35, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 38. A method of ameliorating the effects of exposure to a viral bioterror weapon such as smallpox comprising the following steps:
administering in a pharmaceutically acceptable carrier at least one therapeutic dose of NAC; and administering at least one therapeutic dose of at least one antiviral agent to said viral bioterror weapon.
- 39. The method according to claim 37, further comprising the additional step:
administering a therapeutic dose of selenium.
- 40. The method according to claim 38, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 41. A method of prophylaxis of impending exposure to a viral bioterror weapon such as smallpox comprising the following steps:
administering in a pharmaceutically acceptable carrier a course of therapeutic doses of NAC; and administering a course of prophylactic doses of at least one general antiviral agent to said viral bioterror weapon.
- 42. The method according to claim 41, further comprising the additional step:
administering a therapeutic dose of selenium.
- 43. The method according to claim 42, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 44. The method according to claim 41, further comprising:
selecting said at least one general antiviral agent from the group of cidofovir, Broad spectrum antivirals such as the Triazole carboxamine, Ribavirin, protease inhibitors such as Saquinavir, Ritonavir, Indinavir, and Nelfinavir, tricyclic amines such as Amantadine and Rimantadine, Meuraminic acid mimetics such as Relenza and Tamiflu, small cyclics such as Pleconaril, Nucleoside analogues such as Vidarabine, Acyclovir, Gancyclovir, valganciclovir, Nucleoside Reverse transcriptase inhibitors such as Zidovudine (AZT), Didanosine (dd1), Zaocaitabine (ddC), Stravudine (d4T), and Lamivudine (3TC), and Non-Nucleoside Reverse transcriptase inhibitors such as Nevirapine and Delaviridine,
- 45. The method according to claim 44, further comprising the additional step:
administering a therapeutic dose of selenium.
- 46. The method according to claim 45, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 47. A method of ameliorating the side effects of a vaccine against a bioterror weapon or disease more generally, comprising the following steps:
administering in a pharmaceutically acceptable carrier a course of therapeutic doses of NAC prior to administration of said vaccine; administering said vaccine; continuing said administration of a course of therapeutic does of NAC subsequent to administration of said vaccine at least until any potential side effects of said vaccine are attenuated.
- 48. The method according to claim 47, further comprising the additional step:
administering a therapeutic dose of selenium.
- 49. The method according to claim 48, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 50. A method of ameliorating the side effects of a vaccine against a bioterror weapon or disease more generally, comprising the following steps:
administering said vaccine; administering in a pharmaceutically acceptable carrier a therapeutic dose of NAC contemporaneously to administration of said vaccine.
- 51. The method according to claim 50, further comprising the additional step:
continuing said administration of a course of therapeutic doses of NAC subsequent to administration of said vaccine at least until any potential side effects of said vaccine are attenuated.
- 52. The method according to claim 51, further comprising:
said therapeutic dose of NAC being selected from the group of water soluble NAC compounds.
- 53. The method according to claim 52, further comprising the additional step:
administering a therapeutic dose of selenium.
- 54. The method according to claim 53, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 55. A method of prophylaxis of impending exposure to an impending potential combined viral and bacterial bioterror weapon comprising the following steps:
administering in a pharmaceutically acceptable carrier a course of therapeutic doses of NAC; and administering a course of prophylactic doses of at least one general antibiotic; and administering a course of prophylactic doses of at least one general antiviral agent.
- 56. The method according to claim 55, further comprising the additional step:
administering a therapeutic dose of selenium.
- 57. The method according to claim 56, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 58. The method according to claim 57, further comprising:
selecting said at least one general antiviral agent from the group of cidofovir, Broad spectrum antivirals such as the Triazole carboxamine, Ribavirin, protease inhibitors such as Saquinavir, Ritonavir, Indinavir, and Nelfinavir, tricyclic amines such as Amantadine and Rimantadine, Meuraminic acid mimetics such as Relenza and Tamiflu, small cyclics such as Pleconaril, Nucleoside analogues such as Vidarabine, Acyclovir, Gancyclovir, valganciclovir, Nucleoside Reverse transcriptase inhibitors such as Zidovudine (AZT), Didanosine (dd1), Zaocaitabine (ddC), Stravudine (d4T), and Lamivudine (3TC), and Non-Nucleoside Reverse transcriptase inhibitors such as Nevirapine and Delaviridine; and selecting at least one general antibiotic from the group of Penicillins such as Penicillin, Ampicillin, Nafcillin, or Piperacillin, Beta-lactamase inhibitors such as Aztreonam, Imipenem, Ampicillin/sulbactam (Augmentum) or Pipercillin/tazobactam, or a subgroup including Beta-lactams such as Ceftriaxone, Cefuroxime, Quinolones such as Ciprofloxacin, Ofloxacin, Gatifloxacin or Trovafloxacin, Tetracyclines such as Tetracycline, Doxycycline, or Minocycline, and Macrolides such as Erythromycin, Clarithromycin, or Azithromycin.
- 59. The method according to claim 58, further comprising the additional step:
administering a therapeutic dose of selenium.
- 60. The method according to claim 59, further comprising the additional step:
administering a therapeutic dose of DHEA.
- 61. A method of ameliorating radiation damage, comprising the following step:
administering a therapeutic dose of NAC.
- 62. The method according to claim 61, further comprising the additional step:
administering a therapeutic dose of selenium.
- 63. The method according to claim 62, further comprising the additional step:
administering a therapeutic dose of DHEA.
CONTINUATION DATA
[0001] This application is a continuation in part of provisional application 60/338,267 filed on Nov. 9, 2002 entitled Systemic Administration Of Glutathione Or Precursor Such As NAC As An Adjunct In The Treatment Of Bacillus Anthracis Exposure Or Infection, of provisional application 60/371,590 filed on Apr. 11, 2002 entitled Use Of Glutathione Precursor In The Treatment Of Smallpox And The Use Of Glutathione Precursor In The Treatment Of Radiation Exposure, The Use Of The Combination Of Glutathione Precursor And DHEA For The Treatment Of Smallpox And Other Viruses, and of a provisional application being filed this day with the above title, all of which are incorporated by reference herein.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60371590 |
Apr 2002 |
US |
|
60338267 |
Nov 2001 |
US |